Geode Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Geode Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342K	Buy	242,251 +12,083	+5%	+$14.2K	﹤0.01%	3732
2026 Q1	$309K	Buy	230,168 +24,000	+12%	+$39.5K	﹤0.01%	3765
2025 Q4	$330K	Buy	206,168 +80,928	+65%	+$167K	﹤0.01%	3735
2025 Q3	$321K	Buy	125,240 +97,058	+344%	+$306K	﹤0.01%	3769
2025 Q2	$51K	Buy	28,182 +6,120	+28%	+$10.1K	﹤0.01%	4214
2025 Q1	$44.8K	Buy	22,062 +2,564	+13%	+$9.57K	﹤0.01%	4219
2024 Q4	$117K	Buy	19,498 +870	+5%	+$7.27K	﹤0.01%	4060
2024 Q3	$182K	Buy	18,628 +1,958	+12%	+$26.3K	﹤0.01%	3931
2024 Q2	$341K	Sell	16,670 -11,950	-42%	-$400K	﹤0.01%	3717
2024 Q1	$1.29M	Buy	28,620 +481	+2%	+$22.9K	﹤0.01%	3264
2023 Q4	$1.33M	Buy	28,139 +1,694	+6%	+$94.2K	﹤0.01%	3232
2023 Q3	$1.07M	Buy	26,445 +1,154	+5%	+$117K	﹤0.01%	3289
2023 Q2	$2.69M	Buy	25,291 +1,345	+6%	+$448K	﹤0.01%	3015
2023 Q1	$7.15M	Buy	23,946 +509	+2%	+$217K	﹤0.01%	2464
2022 Q4	$8.05M	Buy	23,437 +1,216	+5%	+$294K	﹤0.01%	2402
2022 Q3	$4.2M	Buy	22,221 +740	+3%	+$172K	﹤0.01%	2762
2022 Q2	$4.54M	Buy	21,481 +2,007	+10%	+$422K	﹤0.01%	2750
2022 Q1	$6.51M	Buy	19,474 +643	+3%	+$186K	﹤0.01%	2635
2021 Q4	$6.13M	Buy	18,831 +266	+1%	+$114K	﹤0.01%	2772
2021 Q3	$9.02M	Buy	18,565 +1,264	+7%	+$556K	﹤0.01%	2525
2021 Q2	$8.04M	Buy	17,301 +1,511	+10%	+$824K	﹤0.01%	2619
2021 Q1	$10.9M	Buy	15,790 +1,775	+13%	+$1.43M	﹤0.01%	2300
2020 Q4	$10.4M	Buy	14,015 +1,130	+9%	+$880K	﹤0.01%	2155
2020 Q3	$8.94M	Buy	12,885 +2,798	+28%	+$2.1M	﹤0.01%	2009
2020 Q2	$8.55M	Buy	10,087 +1,613	+19%	+$1.05M	﹤0.01%	2016
2020 Q1	$3.03M	Buy	8,474 +3,524	+71%	+$1.27M	﹤0.01%	2436
2019 Q4	$1.16M	Buy	4,950 +1,081	+28%	+$109K	﹤0.01%	3228
2019 Q3	$435K	Buy	3,869 +91	+2%	+$14.4K	﹤0.01%	3515
2019 Q2	$662K	Buy	3,778 +2,194	+139%	+$372K	﹤0.01%	3366
2019 Q1	$250K	Buy	+1,584	New	+$195K	﹤0.01%	3669

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management's BTAI Position: Q2 2026 in Review

Geode Capital Management increased its BioXcel Therapeutics (BTAI) stake by 5.2% in Q2 2026, buying an estimated $14.2K and bringing the position to 242,251 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #3732.

Geode Capital Management first reported a position in BTAI in Q1 2019 and has held it in 30 quarters since. The position peaked at $10.9M in Q1 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Geode Capital Management held 242,251 shares of BioXcel Therapeutics worth $342K as of Q2 2026.
Geode Capital Management bought 12,083 BioXcel Therapeutics shares in Q2 2026, an estimated $14.2K.
BioXcel Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3732 holding.
Geode Capital Management first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 30 quarters since.
Geode Capital Management's BioXcel Therapeutics position peaked at $10.9M in Q1 2021.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.